| Precursor |
FNDC5 |
| Length |
112 amino acids (mature) |
| Molecular Weight |
~12 kDa |
| UniProt |
Q8IZF6 |
| Source Tissue |
Skeletal muscle |
| Receptor |
αVβ5 integrin |
| Serum Concentration |
10-100 ng/mL |
| Half-life |
~1 hour |
| Induction |
Exercise (2-3 fold increase) |
| Related Diseases |
Alzheimer's Disease, Parkinson's Disease, ALS |
Irisin is a cleaved, circulating form of the membrane protein FNDC5 (Fibronectin Type III Domain Containing 5) that is primarily produced in skeletal muscle during exercise. Originally discovered in 2012 as a "exercise-induced hormone," irisin has since been shown to have profound effects on energy metabolism, brown adipose tissue thermogenesis, and critically, neuroprotection in models of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
Irisin acts as a systemic mediator, conveying the benefits of exercise to distant tissues including the brain. This positions irisin as a compelling therapeutic target for neurodegenerative diseases where exercise has demonstrated beneficial effects but where pharmacological intervention could amplify or replicate these effects.
¶ Discovery and Nomenclature
- 2012: Irisin was first described by Boström et al. in Nature
- Name origin: Named after Iris, the Greek goddess who crossed between heaven and earth
- Rationale: Irisin crosses the blood-brain barrier and mediates exercise effects on the brain
Irisin is generated through proteolytic cleavage of the full-length FNDC5 protein:
- FNDC5 is expressed in skeletal muscle cells
- The protein is processed by proteases (primarily ADAM17/TACE)
- The extracellular domain is cleaved and released as irisin
- Irisin enters circulation and reaches target tissues
Irisin signals through multiple receptor pathways:
- Identification: Integrin αVβ5 was identified as the functional receptor for irisin
- Signal transduction: Integrin engagement activates downstream signaling cascades
- Tissue distribution: Expressed widely including in brain tissue
- Other integrins: αVβ3 and other integrins may contribute
- Receptor-independent: Some effects may occur through non-classical mechanisms
- Paracrine signaling: Local tissue production may have autocrine/paracrine effects
flowchart TD
A["Irisin"] --> B["αVβ5 Integrin"]
B --> C["FAK Activation"]
C --> D["PI3K/Akt Pathway"]
C --> E["ERK1/2 Pathway"]
C --> F["AMPK Activation"]
D --> G["Cell Survival"]
E --> H["Gene Expression"]
F --> I["Energy Metabolism"]
G --> J["mTOR Activation"]
H --> K["BDNF Expression"]
I --> L["Mitochondrial Biogenesis"]
K --> M["Neuroprotection"]
L --> M
Irisin activates multiple downstream signaling pathways:
| Pathway |
Effect |
Relevance to Neurodegeneration |
| AMPK |
Energy sensing, mitochondrial biogenesis |
Metabolic support |
| ERK1/2 |
Gene expression, cell survival |
Neuroprotection |
| PI3K/Akt |
Cell survival, protein synthesis |
Anti-apoptotic |
| mTOR |
Protein synthesis, autophagy |
Synaptic plasticity |
| PGC-1α |
Mitochondrial biogenesis |
Energy metabolism |
Irisin has shown remarkable benefits in AD models:
- Aβ reduction: Decreased amyloid-beta accumulation in hippocampus and cortex
- Plaque burden: Reduced amyloid plaque formation and burden
- APP processing: Shifted APP processing toward non-amyloidogenic pathway
- Phosphorylation: Reduced tau phosphorylation at multiple epitopes
- Aggregation: Decreased tau oligomerization
- NFT formation: Attenuated neurofibrillary tangle formation
- LTP enhancement: Improved long-term potentiation in hippocampus
- Synaptic markers: Preserved synaptophysin, PSD95 levels
- Spine density: Maintained dendritic spine density
- Memory: Enhanced spatial memory and learning in AD mice
- Behavioral: Improved performance in Morris water maze, Y-maze
- Neurogenesis: Increased hippocampal neurogenesis
Evidence for irisin's neuroprotective effects in PD:
- TH preservation: Maintained tyrosine hydroxylase-positive neurons in substantia nigra
- Fiber density: Preserved striatal dopamine fiber density
- Cell viability: Reduced dopaminergic neuron death
- Aggregation: Reduced α-synuclein aggregation
- Toxicity: Decreased oligomeric α-synuclein toxicity
- Clearance: Enhanced clearance mechanisms
- Biogenesis: Increased PGC-1α expression and mitochondrial DNA
- Complex I: Improved complex I activity
- ROS: Reduced reactive oxygen species
- Behavioral improvement: Enhanced performance in cylinder test, forelimb use
- Locomotion: Improved horizontal and vertical activity
In ALS models:
- Survival: Extended motor neuron survival
- Degeneration: Reduced axonal degeneration
- Neuromuscular junctions: Preserved NMJ integrity
- Innervation: Maintained motor endplate innervation
- Muscle function: Preserved muscle strength
- Denervation: Delayed muscle denervation
¶ Exercise and Irisin
Exercise is the primary physiological stimulus for irisin release:
| Exercise Type |
Irisin Increase |
Duration |
| Aerobic (running) |
2-3 fold |
2-4 hours |
| Resistance training |
1.5-2 fold |
1-2 hours |
| High-intensity interval |
2-3 fold |
Peak at 1 hour |
| Chronic exercise |
Sustained elevation |
Days to weeks |
Exercise induces irisin through:
- PGC-1α activation: Exercise increases PGC-1α in muscle
- FNDC5 transcription: PGC-1α directly upregulates FNDC5 gene expression
- Proteolytic processing: Enhanced ADAM17 activity increases cleavage
- Secretion: Release into systemic circulation
For maximizing irisin-mediated neuroprotection:
- Frequency: 3-5 sessions per week
- Duration: 30-60 minutes per session
- Intensity: Moderate to vigorous (65-85% HRmax)
- Type: Aerobic exercise most effective; resistance training complementary
- Direct delivery of active protein
- Well-characterized mechanism
- Potential for CNS delivery
- Blood-brain barrier penetration
- Short circulating half-life (~1 hour)
- Manufacturing scalability
- Dosing optimization
- AAV-FNDC5: Adeno-associated virus-mediated FNDC5 expression
- mRNA delivery: Lipid nanoparticle mRNA encoding FNDC5
- CRISPR activation: Epigenetic upregulation of endogenous FNDC5
- Preclinical studies ongoing
- AAV delivery to brain demonstrated safety
- Efficacy shown in AD mouse models
| Target |
Compound Class |
Status |
| PGC-1α |
PPAR agonists |
Research |
| AMPK |
Metformin, AICAR |
Research |
| FNDC5 transcription |
HDAC inhibitors |
Research |
| Irisin mimetics |
Peptide analogs |
Research |
Compounds that replicate exercise effects:
- PGC-1α agonists: Direct activation of PGC-1α
- AMPK activators: Pharmacological AMPK activation
- SIRT1 activators: Resveratrol and analogs
Irisin as a biomarker:
- Serum levels: Readily measurable by ELISA
- Exercise correlation: Correlates with exercise intensity
- Disease association: Altered levels in AD, PD, diabetes
- Therapeutic monitoring: Potential treatment response marker
Current status:
- Exercise intervention trials measuring irisin
- Safety studies for recombinant irisin
- Phase I trials anticipated for irisin analogs
| Challenge |
Impact |
Mitigation Strategy |
| BBB penetration |
Limited brain delivery |
Intranasal, focused ultrasound |
| Half-life |
Short duration |
PEGylation, fusion proteins |
| Dosing |
Unknown optimal dose |
Biomarker-guided dosing |
| Specificity |
Off-target effects |
Targeted delivery |
- FNDC5 — Precursor gene
- PGC-1α — Transcriptional regulator
- AMPK — Energy sensor
- BDNF — Neurotrophic factor